| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| 10mg |
|
||
| 25mg |
|
||
| 100mg |
|
||
| 250mg | |||
| Other Sizes |
| Targets |
PE859 targets tau protein and amyloid-β (Aβ) aggregation. It is a potent inhibitor of both tau and Aβ aggregation with IC₅₀ values of 0.66 μM and 1.2 μM, respectively. The compound binds to aggregation-prone regions of tau, preventing abnormal aggregation and neurofibrillary tangle formation.
|
|---|---|
| ln Vitro |
In a concentration-dependent manner, PE859 prevents full-length tau aggregation and 3RMBD caused by heparin. The last measurement cycle's estimated IC50 values for each assay were 2.23 μM and 0.81 μM, respectively. PE859 forms β-sheet structures that prevent tau aggregation [2].
In vitro, PE859 inhibits heparin-induced aggregation of both 3RMBD and full-length tau in a concentration-dependent manner with IC₅₀ values of 0.81 μM and 2.23 μM, respectively. It also inhibits Aβ aggregation with an IC₅₀ of 1.2 μM. The compound inhibits tau aggregation through formation of β-sheet structure. |
| ln Vivo |
PE859 has the ability to penetrate the blood-brain barrier and permeate into central nervous system tissues. PE859 reached its maximal concentrations in the blood at 2.005 μg/mL and the brain at 1.428 μg/g after three and six hours, respectively. In JNPL3 mice, PE859 postpones the onset and development of motor impairment. PE859 inhibits the aggregation of tau protein that is sarkosyl-insoluble, hence delaying the evolution of motor dysfunction. [2]
In vivo, PE859 crosses the blood-brain barrier and distributes into central nervous system tissues. It delays the onset and progression of motor dysfunction in JNPL3 mouse models of tauopathy by inhibiting the accumulation of sarkosyl-insoluble tau. Maximum concentration is 2.005 μg/mL in blood at 3 h and 1.428 μg/g in brain at 6 h. |
| Enzyme Assay |
Non-cellular assays for PE859 include heparin-induced tau aggregation inhibition assays. Recombinant tau protein (3RMBD or full-length) is incubated with heparin and varying concentrations of PE859. Aggregation is monitored by fluorescence using thioflavin T or other probes. IC₅₀ values are calculated from dose-response curves at the end of the incubation period.
|
| Cell Assay |
In vitro cellular experiments involve treating neuronal cell lines or primary neurons with PE859 to assess its effects on tau and Aβ aggregation. Cells expressing tau or Aβ are treated with the compound at various concentrations, and protein aggregation is measured by biochemical assays such as Western blot or ELISA. Cell viability and neuroprotection are also assessed.
|
| Animal Protocol |
In vivo animal studies utilize transgenic mouse models of tauopathy, such as JNPL3 mice, or Alzheimer's disease models. PE859 is administered via appropriate routes, and behavioral assessments including motor function tests are performed. Brain tissue is analyzed for sarkosyl-insoluble tau levels and other biomarkers to evaluate efficacy.
|
| ADME/Pharmacokinetics |
PE859 is brain-penetrant and distributes into central nervous system tissues. After oral or parenteral administration, the compound reaches a maximum concentration of 2.005 μg/mL in blood at 3 hours and 1.428 μg/g in brain at 6 hours. The compound is stable for 3 years as powder at -20°C.
|
| Toxicity/Toxicokinetics |
Specific toxicity data for PE859 is limited in publicly available sources. As a tau and Aβ aggregation inhibitor being studied for neurodegenerative diseases, standard preclinical toxicology studies would be required. The compound is for research purposes only and should be handled with appropriate safety precautions.
|
| References |
|
| Additional Infomation |
PE859 is a potent, brain-penetrant inhibitor of both tau and Aβ aggregation with IC₅₀ values of 0.66 and 1.2 μM, respectively. It is a novel tau aggregation inhibitor that reduces aggregated tau and prevents the onset and progression of neural dysfunction in vivo. This product is for research purposes only and is not for human therapeutic use.
|
| Molecular Formula |
C28H24N4O2
|
|---|---|
| Molecular Weight |
448.526
|
| Exact Mass |
448.189
|
| CAS # |
1402727-29-0
|
| PubChem CID |
66571561
|
| Appearance |
Light yellow to khaki solid powder
|
| Density |
1.3±0.1 g/cm3
|
| Boiling Point |
747.7±60.0 °C at 760 mmHg
|
| Flash Point |
249.8±23.1 °C
|
| Vapour Pressure |
0.0±2.4 mmHg at 25°C
|
| Index of Refraction |
1.768
|
| LogP |
5.47
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
4
|
| Rotatable Bond Count |
8
|
| Heavy Atom Count |
34
|
| Complexity |
685
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
COC1=C(C=CC(=C1)OCC2=CC=CC=N2)/C=C/C3=CC(=NN3)/C=C/C4=CC5=C(C=C4)C=CN5
|
| InChi Key |
AMBZHNVCLPHAKA-NSJFVGFPSA-N
|
| InChi Code |
InChI=1S/C28H24N4O2/c1-33-28-18-26(34-19-25-4-2-3-14-29-25)12-9-22(28)8-11-24-17-23(31-32-24)10-6-20-5-7-21-13-15-30-27(21)16-20/h2-18,30H,19H2,1H3,(H,31,32)/b10-6+,11-8+
|
| Chemical Name |
6-[(E)-2-[5-[(E)-2-[2-methoxy-4-(pyridin-2-ylmethoxy)phenyl]ethenyl]-1H-pyrazol-3-yl]ethenyl]-1H-indole
|
| Synonyms |
PE 859; PE-859; PE859
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~50 mg/mL (~111.48 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (5.57 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (5.57 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of corn oil and mix evenly. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.2295 mL | 11.1475 mL | 22.2951 mL | |
| 5 mM | 0.4459 mL | 2.2295 mL | 4.4590 mL | |
| 10 mM | 0.2230 mL | 1.1148 mL | 2.2295 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
